Weekly patient-reported symptom monitoring was associated with longer survival across all stages of lung cancer

Design

Post hoc survival analysis of a stepped-wedge cluster-randomised trial

Population

446 patients with stage I–IV lung cancer starting treatment at 14 Dutch hospitals

Primary outcome

Overall survival

Effect

Median 26 vs 21 months; adjusted HR 0.80 (95% CI 0.63–1.00)

SYMPRO-Lung was a stepped-wedge, cluster-randomised trial at 14 hospitals in the Netherlands. All sites began with usual care and crossed over, at randomly assigned times, to an intervention in which patients completed weekly online symptom questionnaires for a year. Patients had stage I–IV lung cancer and were starting new treatment. Quality of life, the primary outcome, was reported earlier; this post hoc analysis linked 446 patients to the national cancer registry for survival.

At a median follow-up of 50 months, median overall survival was 26 months with symptom monitoring against 21 months with usual care. After adjustment for age, sex, stage, histology, performance status and treatment line, the hazard ratio was 0.80 (95% CI 0.63–1.00, p = 0.049). Progression-free survival did not differ significantly (HR 0.86, 0.70–1.07).

The result fits earlier trials in advanced cancer showing survival gains from symptom monitoring, and extends them to earlier-stage disease in routine care. The plausible mechanism is earlier action on symptoms and toxicity, keeping patients fit enough to continue treatment. But the result is post hoc, the confidence interval touches 1, and 13% of the original cohort could not be included. It is strong enough to support building symptom monitoring into lung cancer services, not proof of a five-month gain for every patient.

• Consider routine weekly patient-reported symptom monitoring for patients starting lung cancer treatment.
• Make sure alerts from symptom reports reach a clinician who can act on them the same day.
• Simple online or phone-based questionnaires were enough; the intervention did not need research-level resources.
• Include early-stage patients, not only those with advanced disease.
• Offer a paper or phone alternative for patients without reliable internet access.

Why it matters

A low-cost process change may matter for survival as much as some drug additions.

Don't overread it

This was a post hoc survival analysis with a confidence interval reaching 1.00; it is supportive, not definitive.

The statistics, in plain English

A hazard ratio of 0.80 suggests about 20% lower risk of death at any time, but the upper limit of 1.00 means no effect is only just excluded. Because survival was not the trial's primary outcome, the result needs confirmation.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.